Further studies will be needed to address the impact of PD-L1 expression on the necessity of adding CT and to establish whether patients with high PD-L1 (≥50%) could benefit from a CT-free immunotherapy treatment in advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.